Bailif Tablets (Tenofovir Disoproxil)

Adult dose

Adults For the treatment of HIV-1 or chronic hepatitis B, take 1 tablet once daily (equivalent to 245mg of tenofovir disoproxil). It may be taken with or without food. The optimal duration of treatment for chronic hepatitis B is unknown. Patients with renal impairment In patients with baseline creatinine clearance <50mL/min, adjust the dosing interval according to Table 1. No adjustment of the dosing interval is necessary in patients with mild renal impairment (creatinine clearance 50-80mL/min); routinely monitor calculated creatinine clearance and serum phosphate (see Warning 3). Table 1. Dosing interval adjustment according to creatinine clearance Creatinine clearance (mL/min)a ≥50: every 24 hours 30-49: every 48 hours 10-29: every 72-96 hours Patients on hemodialysis: every 7 days or approximately 12 hours after dialysisb a. Calculated using ideal (lean body) weight. b. Administer once weekly, generally assuming 3 hemodialysis sessions of approximately 4 hours each per week. This medicine should be administered after dialysis is completed. The pharmacokinetics of tenofovir have not been evaluated in patients with creatinine clearance below 10mL/min who are not receiving hemodialysis; therefore, no dosing recommendations are available for these patients.

Child dose

Pediatric patients aged 12 years and older (35kg or more): For the treatment of HIV-1 or chronic hepatitis B, take 1 tablet once daily (equivalent to 245mg of tenofovir disoproxil). It may be taken with or without food. Safety and efficacy have not been established in pediatric patients with chronic hepatitis B weighing less than 35kg. No data are available to support dose recommendations for pediatric patients with renal impairment.

This drug may cause a sudden exacerbation of hepatitis if treatment is stopped, therefore regular examinations must be conducted for several months after discontinuation. Do not take this drug if you are allergic to its components or have certain hereditary lactose metabolism disorders. It is prohibited to use this drug in conjunction with other medications containing the same ingredient or specific drugs, so consultation with a physician is mandatory. Patients with impaired kidney function should undergo a kidney function test before taking this drug and regularly check their kidney function during treatment. Caution is necessary when used with other medications that can burden the kidneys, particularly non-steroidal anti-inflammatory drugs (NSAIDs) should not be used in combination. Bone health may be affected, so patients with low bone density or at risk for osteoporosis should consider bone density testing according to their doctor's instructions. This drug contains sulfite components and may cause allergic reactions or asthma symptoms, so those with a history of sulfite allergy should use caution. It can be used during pregnancy, but should be taken under medical supervision when necessary, and breastfeeding is not recommended as the medication can be passed through breast milk. The safety and efficacy of this drug have not been sufficiently established in children under 12 years of age or those weighing less than 35 kg. Elderly patients may have decreased liver or kidney function, so caution is needed during use. In case of overdose, contact a medical institution immediately for appropriate treatment, and some components of this drug can be removed through dialysis. This drug should be stored at room temperature, and kept safely out of reach of children.

• Worsening of hepatitis
• hypersensitivity
• acute renal failure
• Fanconi syndrome
• renal impairment
• bone pain
• limb pain
• fractures
• muscle pain
• muscle weakness

This drug may be sensitive to air and moisture, so it must be stored in a closed container. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. This will help preserve the drug's efficacy and safety for a long time.

Appearance

Light blue almond-shaped film-coated tablets

Package unit

30 tablets/bottle